Resolving Mechanistic Heterogeneity Through Precision Medicine and Staged Inter…

The Skeptic’s critique, while raising legitimate concerns about delivery and heterogeneity, fundamentally mischaracterizes the proposed therapeutic strategy by treating it as a monolithic intervention rather than a precision medicine framework. The eRNA approach is explicitly designed for the genetically defined subset of ALS-FTD patients where TDP-43 mutations create identifiable pathological RNA interactomes—the approximately 5% of ALS cases with TARDBP mutations and the significant fraction of FTD cases with GRN mutations that secondarily alter TDP-43 function. I have never claimed this approach applies uniformly to all ALS-FTD patients. Rather, I propose a stratified therapeutic strategy where eRNA interventions target the subset with characterized pathological RNA-TDP-43 interactions, while independent approaches address sporadic ALS through distinct mechanisms such as proteostasis stabilization or stress granule modulation. The delivery concerns, while valid for AAV-PHP.eB in adult humans, ignore the rapidly evolving landscape of CNS RNA delivery technologies. Lipid nanoparticles (LNPs) have demonstrated robust mRNA delivery to the CNS in non-human primates at clinically relevant doses (PMID:35294805), and conjugating these to antibodies against transferrin receptor enables BBB transcytosis (PMID:34619125). These platforms are already in clinical development for other neurological conditions and represent near-term translational opportunities rather than distant theoretical possibilities. The Skeptic’s reliance on mouse-specific AAV capsid limitations to dismiss the entire delivery modality reflects a failure to appreciate platform evolution. ## Addressing Heterogeneity Through Mechanistic Subsetting The critical insight from the Skeptic’s heterogeneity argument is that it supports rather than undermines the precision therapeutic approach. ALS-FTD represents a final common clinical phenotype arising from multiple distinct pathogenic mechanisms, all converging on TDP-43 dysfunction. Just as we would not expect a single chemotherapy to treat all cancers, we should not expect a single TDP-43-targeted therapy to address all ALS-FTD subtypes. The disease heterogeneity I acknowledged in Round 2—where familial ALS with TDP-43 mutations proceeds through the pathological RNA interactome while sporadic ALS may originate from distinct upstream insults—actually predicts differential therapeutic responses that can be prospectively identified through biomarker s

Debate provenance: derived from debate DA-2026-04-11-093252-90e0375b on question: TDP-43 phase separation therapeutics for ALS-FTD. Consensus signal: domain_expert, falsifier, skeptic, synthesizer, theorist discussed the mechanism terms AAV, ALS, BBB, CNS, FTD, GRN, Heterogeneity, Intervention. Novelty signal: skeptic-discussed-with-qualified-concession.